Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 177

1.

The prognostic significance of thrombocytosis in uterine papillary serous carcinomas.

Lerner DL, Walsh CS, Cass I, Karlan BY, Li AJ.

Gynecol Oncol. 2007 Jan;104(1):91-4. Epub 2006 Aug 24.

PMID:
16934317
2.

The prognostic significance of thrombocytosis in epithelial ovarian carcinoma.

Li AJ, Madden AC, Cass I, Leuchter RS, Lagasse LD, Karlan BY.

Gynecol Oncol. 2004 Jan;92(1):211-4.

PMID:
14751160
3.

The role of cytoreductive surgery in the management of stage IV uterine papillary serous carcinoma.

Bristow RE, Duska LR, Montz FJ.

Gynecol Oncol. 2001 Apr;81(1):92-9.

PMID:
11277657
4.

Prognostic significance of preoperative thrombocytosis in patients with endometrial carcinoma in an inner-city population.

Gorelick C, Andikyan V, Mack M, Lee YC, Abulafia O.

Int J Gynecol Cancer. 2009 Nov;19(8):1384-9. doi: 10.1111/IGC.0b013e3181a47d47.

PMID:
20009894
5.

Role of cytoreduction in stage III and IV uterine papillary serous carcinoma.

Thomas MB, Mariani A, Cliby WA, Keeney GL, Podratz KC, Dowdy SC.

Gynecol Oncol. 2007 Nov;107(2):190-3. Epub 2007 Sep 6.

PMID:
17825394
6.

Utility of pre-operative serum CA-125 in the management of uterine papillary serous carcinoma.

Olawaiye AB, Rauh-Hain JA, Withiam-Leitch M, Rueda B, Goodman A, del Carmen MG.

Gynecol Oncol. 2008 Sep;110(3):293-8. doi: 10.1016/j.ygyno.2008.05.027. Epub 2008 Jul 21.

PMID:
18644620
7.

Uterine papillary serous carcinoma (UPSC): a single institution review of 129 cases.

Slomovitz BM, Burke TW, Eifel PJ, Ramondetta LM, Silva EG, Jhingran A, Oh JC, Atkinson EN, Broaddus RR, Gershenson DM, Lu KH.

Gynecol Oncol. 2003 Dec;91(3):463-9. Review.

PMID:
14675663
8.

Uterine papillary serous, clear cell, and poorly differentiated endometrioid carcinomas: a comparative study.

Greggi S, Mangili G, Scaffa C, Scala F, Losito S, Iodice F, Pisano C, Montoli S, Viganò R, Pirozzi G, Giannarelli D.

Int J Gynecol Cancer. 2011 May;21(4):661-7. doi: 10.1097/IGC.0b013e3182150c89.

PMID:
21412164
9.

Preoperative thrombocytosis predicts poor survival in patients with glioblastoma.

Brockmann MA, Giese A, Mueller K, Kaba FJ, Lohr F, Weiss C, Gottschalk S, Nolte I, Leppert J, Tuettenberg J, Groden C.

Neuro Oncol. 2007 Jul;9(3):335-42. Epub 2007 May 15.

10.

Racial differences in the overexpression of epidermal growth factor type II receptor (HER2/neu): a major prognostic indicator in uterine serous papillary cancer.

Santin AD, Bellone S, Siegel ER, Palmieri M, Thomas M, Cannon MJ, Kay HH, Roman JJ, Burnett A, Pecorelli S.

Am J Obstet Gynecol. 2005 Mar;192(3):813-8.

PMID:
15746676
11.

Improved survival in surgical stage I patients with uterine papillary serous carcinoma (UPSC) treated with adjuvant platinum-based chemotherapy.

Kelly MG, O'malley DM, Hui P, McAlpine J, Yu H, Rutherford TJ, Azodi M, Schwartz PE.

Gynecol Oncol. 2005 Sep;98(3):353-9.

PMID:
16005947
12.

The effect of adjuvant chemotherapy versus whole abdominopelvic radiation on the survival of patients with advanced stage uterine papillary serous carcinoma.

Hamilton CA, Cheung MK, Osann K, Balzer B, Berman ML, Husain A, Teng NN, Kapp DS, Chan JK.

Gynecol Oncol. 2006 Nov;103(2):679-83. Epub 2006 Jun 21.

PMID:
16793126
13.

Prognostic determinants in patients with stage IIIC and IV uterine papillary serous carcinoma.

Rauh-Hain JA, Growdon WB, Schorge JO, Goodman AK, Boruta DM, McCann C, Horowitz NS, del Carmen MG.

Gynecol Oncol. 2010 Nov;119(2):299-304. doi: 10.1016/j.ygyno.2010.07.010. Epub 2010 Aug 5.

PMID:
20691465
14.

Outcome after combined modality treatment for uterine papillary serous carcinoma: a study by the Rare Cancer Network (RCN).

Goldberg H, Miller RC, Abdah-Bortnyak R, Steiner M, Yildiz F, Meirovitz A, VillĂ  S, Poortmans PM, Azria D, Zidan J, Ozsahin M, Abacioglu U, Gold DG, Amit A, Lavie O, Atahan IL, Kuten A; Rare Cancer Network.

Gynecol Oncol. 2008 Feb;108(2):298-305. Epub 2007 Dec 21.

PMID:
18096209
15.

Thrombocytosis in advanced epithelial ovarian cancer.

Soonthornthum T, Suraseraneewong V, Kengsakol K, Wijaithum K, Kasemsan P, Prommatt S.

J Med Assoc Thai. 2007 Aug;90(8):1495-500.

PMID:
17926975
16.

Micropapillary serous ovarian carcinoma: surgical management and clinical outcome.

Bristow RE, Gossett DR, Shook DR, Zahurak ML, Tomacruz RS, Armstrong DK, Montz FJ.

Gynecol Oncol. 2002 Aug;86(2):163-70.

PMID:
12144823
17.

The incidence of pelvic and para-aortic lymph node metastasis in uterine papillary serous and clear cell carcinoma according to the SEER registry.

Mattes MD, Lee JC, Metzger DJ, Ashamalla H, Katsoulakis E.

J Gynecol Oncol. 2015 Jan;26(1):19-24. doi: 10.3802/jgo.2015.26.1.19. Epub 2014 Oct 13.

18.

Patients with uterine papillary serous cancers may benefit from adjuvant platinum-based chemoradiation.

Kelly MG, O'Malley D, Hui P, McAlpine J, Dziura J, Rutherford TJ, Azodi M, Chambers SK, Schwartz PE.

Gynecol Oncol. 2004 Dec;95(3):469-73.

PMID:
15581948
19.

p53 protein overexpression: a strong prognostic factor in uterine papillary serous carcinoma.

Bancher-Todesca D, Gitsch G, Williams KE, Kohlberger P, Neunteufel W, Obermair A, Heinze G, Breitenecker G, Hacker NF.

Gynecol Oncol. 1998 Oct;71(1):59-63.

PMID:
9784320
20.

Human kallikrein 6: a new potential serum biomarker for uterine serous papillary cancer.

Santin AD, Diamandis EP, Bellone S, Soosaipillai A, Cane S, Palmieri M, Burnett A, Roman JJ, Pecorelli S.

Clin Cancer Res. 2005 May 1;11(9):3320-5.

Supplemental Content

Support Center